EW241220C85000
- 0.11
- +0.06+120.00%
Edwards Lifesciences Newsroom
Edwards Lifesciences Analyst Ratings
Citi Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $83
Truist Financial Maintains Edwards Lifesciences(EW.US) With Hold Rating, Maintains Target Price $78
A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $75 to $90
Oppenheimer Remains a Buy on Edwards Lifesciences (EW)
Edwards Lifesciences (EW) Receives a Buy From RBC Capital
Bank of America Securities Keeps Their Hold Rating on Edwards Lifesciences (EW)
Hold Rating for Edwards Lifesciences: Balancing Risks and Opportunities Amidst Market Variability
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Evolent Health (EVH) and Palisade Bio (PALI)
Edwards Lifesciences Is Maintained at Hold by Canaccord Genuity
Edwards Lifesciences Analyst Ratings
Mizuho Adjusts Price Target on Edwards Lifesciences to $85 From $78, Keeps Outperform Rating
Barclays Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $88
Barclays Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $88
Barclays Adjusts Price Target on Edwards Lifesciences to $88 From $85
Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $80
Edwards Lifesciences (EW) Receives a Hold From Leerink Partners
Edwards Lifesciences Is Maintained at Outperform by RBC Capital
Edwards Lifesciences Analyst Ratings
RBC Capital Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $80